We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sigma-Aldrich Acquires Molecular Medicine BioServices
News

Sigma-Aldrich Acquires Molecular Medicine BioServices

Sigma-Aldrich Acquires Molecular Medicine BioServices
News

Sigma-Aldrich Acquires Molecular Medicine BioServices

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sigma-Aldrich Acquires Molecular Medicine BioServices"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sigma-Aldrich Corporation has announced that it has acquired Molecular Medicine BioServices Inc. (MMB), a biopharmaceutical contract manufacturing organization (CMO) located in Carlsbad, California, to further enhance the biologics capabilities within its SAFC Pharma business segment.

With $12 million in annualized revenues, the acquisition of MMB is expected to help Sigma-Aldrich achieve its growth goals in key high technology markets over the next several years and will be neutral to earnings in 2007 with no significant initial charges. Terms of the purchase, which were not disclosed, were paid in cash.

David Backer, President of MMB, an equity holder and one of the company's founders, will continue as Site Director for SAFC's newest business. All current employees in good standing, including all of MMB's existing management team, will be retained.

MMB was founded in 1997 and employs 60 people at its 23,700 square foot laboratory and headquarters building and 21,400 square foot manufacturing facilities in Carlsbad. Its core expertise is in the development and clinical manufacturing of viral products, drawing on technology to deliver DNA, RNA and critical active ingredients for the production of novel vaccines and gene therapies.

Since its inception, the company has expanded its capabilities from the use of flat-stock cell factories to the extensive use of stir tanks and economic, disposable bioreactor systems. Significantly enhancing SAFC Pharma's oncology offer, MMB has produced clinical grade drug products for a variety of different cancer indicators including head, neck, prostate and pancreatic cancers, as well as for other therapeutic indicators including Alzheimer's disease and Cardiovascular disease.

Frank Wicks, President of SAFC, commented: "The acquisition of MMB continues our push into niche biologics, giving us the critical capability to manufacture virus. It also complements both our new transgenic extraction and purification facility which opened last month in St. Louis and our potent bacterial fermentation facility currently under construction in Israel."

"MMB's experienced team, capabilities and relationships with key end-users, combined with SAFC's global presence and financial strength, will allow us to work together to provide the pharmaceutical industry with better, more specialized, high-quality materials to meet customer needs and demand."

The transaction was initiated by Fairmount Partners, a specialty healthcare investment banking firm based in Philadelphia, PA, who acted as advisor to Molecular Medicine. Bryan Cave LLP acted as legal advisor to Sigma-Aldrich Corporation.

Advertisement